A 2026 Phase 1 trial showed that MSC-derived exosomes injected into the ear were safe and improved hearing in patients with sudden sensorineural hearing loss. Here’s what the breakthrough means and when it could be available.
A 2025 clinical trial reports the first-ever strength improvement in ALS patients using intranasally delivered MSC exosomes — zero adverse events across 32 treatments.
A June 2026 study shows that senolytic preconditioning dramatically improves MSC efficacy by removing the SASP factors that suppress tissue repair. Plus: AAT-MSCs reverse diabetes via immune reprogramming, and a phase III MSC trial for meniscal repair reaches completion.
A 2026 real-world study followed 120 refractory lupus nephritis patients treated with UC-MSCs. Cumulative renal response reached 56.7% at 12 months with low relapse rates and zero severe adverse events. Here’s what clinicians need to know.
36-месячное клиническое исследование показало отсутствие побочных эффектов и снижение боли на 571 TP3T при инъекции стволовых клеток в разорванные вращательные манжеты плеча. Вот что нужно знать любителям спорта и спортсменам-любителям о терапии МСК при спортивных травмах.
The MERIT phase 1 trial published in Cell Reports Medicine shows that intravenous UC-MSC therapy is safe in subacute ischemic stroke, with early NIHSS improvement signals. Here’s what clinicians need to know.
A 2026 meta-analysis of 15 RCTs shows MSCs cut acute GvHD incidence by 53% and chronic GvHD by 50%. A biomarker-guided trial identifies which transplant patients benefit most — and a cell-free exosome approach may be next.
Your body’s stem cell population drops dramatically after 40. Here’s what the science says about why we age — and how regenerative medicine is fighting back.
Discover how mesenchymal stem cell therapy is helping COPD, pulmonary fibrosis, and post-COVID lung damage patients breathe easier — right here in Bangkok, Thailand.
MSC-derived exosomes are reshaping regenerative medicine — learn how these nano-sized vesicles deliver therapy without the risks of whole-cell transplantation.
Russian 
English 
Chinese 
French